Oxolife, a biotech company specializing in female fertility, has announced promising results from a Phase 2 clinical trial of its non-hormonal fertility pill, OXO-001, at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting in Amsterdam. The data indicates that OXO-001 significantly improves embryo implantation, pregnancy, and live birth rates in women undergoing in-vitro fertilization (IVF) and intracytoplasmic sperm…
Menarini Silicon Biosystems (MSB) has presented data at the 2024 Fetal Medicine Foundation (FMF) World Congress in Lisbon, Portugal, demonstrating the accuracy of their cell-based non-invasive prenatal testing (NIPT) technology. The study results indicate that their technology can detect fetal genomic abnormalities through a maternal blood draw with high resolution. MSB offers unique rare cell technologies and solutions that provide clinical researchers…
Papcup has introduced a non-invasive, at-home device designed to screen for cancer-causing HPV strains using regular menstrual blood. This device, developed with support from the Venture Builder Incubator (VBI) at the University of Edinburgh, aims to provide an alternative to traditional smear tests, which many women find uncomfortable and inconvenient. The device offers a highly accurate, non-invasive method for testing, allowing women…
Serac Healthcare, a clinical radiopharmaceutical company specializing in innovative molecular imaging technologies, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualization and diagnosis of superficial peritoneal endometriosis in women aged 16 and older. Fast Track designation is a process designed to facilitate the development and expedite…
Gameto, a biotech firm dedicated to women’s health, has announced the successful closure of a $33 million Series B financing round. This round, which exceeded initial targets, was led by Two Sigma Ventures and RA Capital, with participation from existing investors such as Insight Partners, Future Ventures, and BOLD Capital Partners. New investors include Olivia Walton’s Ingeborg Investments, Stacey Bendet Eisner, and…
Epstein-Barr Virus (EBV) is a ubiquitous herpesvirus that infects over 90% of the global population. It’s most commonly known for causing infectious mononucleosis (IM), or “mono,” but it has also been implicated in several serious conditions, including various cancers (such as Burkitt’s lymphoma and nasopharyngeal carcinoma), autoimmune diseases (like multiple sclerosis), and post-transplant lymphoproliferative disorder (PTLD). Research into EBV has highlighted potential…
Vaginal health takes center stage as Seed Health, a microbiome science company, unveils its latest innovation: VS-01 Vaginal Synbiotic. With a focus on redefining vaginal care, VS-01 represents a new vaginal synbiotic clinically validated to establish and sustain an optimal vaginal microbiome. Developed in collaboration with renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01 aims to address the critical role of the…
Labcorp has launched a new first trimester preeclampsia screening test, making it the only laboratory in the United States to offer preeclampsia risk detection across all pregnancy trimesters, according to the company. The test, designed to be performed between 11 and 14 weeks of gestation, determines the risk of developing preeclampsia before 34 weeks of pregnancy. This innovation is significant for all…
